Asset Details
MbrlCatalogueTitleDetail
Do you wish to reserve the book?
Advancing Decentralized and Pragmatic Clinical Trials as a Path Toward Improved Representativeness and Greater Generalizability of Clinical Trial Evidence
by
Abernethy, Amy P.
, Chaiyachati, Krisda H.
, Washington, Vindell
, Marra, Caroline
in
Clinical trial representativeness
/ Clinical trials
/ Clinical Trials as Topic - methods
/ Data collection
/ Decentralized clinical trial
/ Design
/ Electronic health records
/ Evidence generalizability
/ FDA approval
/ Health care
/ Humans
/ Internal Medicine
/ Participation
/ Patient Selection
/ Pragmatic clinical trial
/ Pragmatic Clinical Trials as Topic - methods
/ Research Design
/ Socioeconomic factors
/ Telemedicine
2025
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Advancing Decentralized and Pragmatic Clinical Trials as a Path Toward Improved Representativeness and Greater Generalizability of Clinical Trial Evidence
by
Abernethy, Amy P.
, Chaiyachati, Krisda H.
, Washington, Vindell
, Marra, Caroline
in
Clinical trial representativeness
/ Clinical trials
/ Clinical Trials as Topic - methods
/ Data collection
/ Decentralized clinical trial
/ Design
/ Electronic health records
/ Evidence generalizability
/ FDA approval
/ Health care
/ Humans
/ Internal Medicine
/ Participation
/ Patient Selection
/ Pragmatic clinical trial
/ Pragmatic Clinical Trials as Topic - methods
/ Research Design
/ Socioeconomic factors
/ Telemedicine
2025
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
Advancing Decentralized and Pragmatic Clinical Trials as a Path Toward Improved Representativeness and Greater Generalizability of Clinical Trial Evidence
by
Abernethy, Amy P.
, Chaiyachati, Krisda H.
, Washington, Vindell
, Marra, Caroline
in
Clinical trial representativeness
/ Clinical trials
/ Clinical Trials as Topic - methods
/ Data collection
/ Decentralized clinical trial
/ Design
/ Electronic health records
/ Evidence generalizability
/ FDA approval
/ Health care
/ Humans
/ Internal Medicine
/ Participation
/ Patient Selection
/ Pragmatic clinical trial
/ Pragmatic Clinical Trials as Topic - methods
/ Research Design
/ Socioeconomic factors
/ Telemedicine
2025
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Advancing Decentralized and Pragmatic Clinical Trials as a Path Toward Improved Representativeness and Greater Generalizability of Clinical Trial Evidence
Journal Article
Advancing Decentralized and Pragmatic Clinical Trials as a Path Toward Improved Representativeness and Greater Generalizability of Clinical Trial Evidence
2025
Request Book From Autostore
and Choose the Collection Method
Overview
Despite efforts to improve research equity in clinical trials, a lack of representativeness continues to threaten the generalizability of clinical trial evidence and leads to several ethical and economic consequences. Decentralized clinical trials (DCTs) and pragmatic clinical trials (PCTs), novel clinical trial models that use technology to enable alternative data collection methods and integrate studies into clinical care, hold great promise for addressing representativeness challenges but also face several limitations. Leveraging technology and clinical care settings to conduct trial visits and collect trial data inherently limits participation from people without reliable access to technology and consistent medical care. Further, representativeness needs to be improved across the full spectrum of clinical trials, from trials conducted in early product development phases to trials conducted after a product is approved, but the DCT and PCT elements that can improve representativeness are more likely to be deployed after seminal evidence for a new medical product’s regulatory approval has already been generated. We propose three solutions to help ensure the defining aspects of DCTs and PCTs increase representativeness and the generalizability of evidence generated in clinical trials conducted at all phases in the product lifecycle. We suggest that efforts should be centered around collaborative work with regulators to define data standards and validate outcomes when alternative data sources and collection methods are used, the creation of technical support resources and transparent processes for the conduct of trials facilitated by technology, and the incorporation of health equity principles into the design and deployment of technology-based tools used to facilitate DCTs and PCTs.
Publisher
Elsevier Inc,Elsevier Limited
This website uses cookies to ensure you get the best experience on our website.